Last reviewed 2026-04-20 · How we verify

Statocin (CARGUTOCIN)

Phase 2 active Recombinant protein Quality 19/100

Statocin (generic name: CARGUTOCIN) is a cargutocin drug. It is currently in Phase 2 development.

Statocin works by binding to a specific target, although the exact target is unknown.

Statocin, also known as Cargutocin, is a small molecule drug of the cargutocin class. Unfortunately, there is limited information available on this drug, including its target, approved indications, and commercial status. As a result, it is difficult to provide a comprehensive summary of its use and safety profile. Further research is needed to determine the efficacy and safety of Statocin in clinical settings. Without more information, it is challenging to assess its potential as a treatment option.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CARGUTOCIN
Drug class	cargutocin
Modality	Recombinant protein
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Statocin is a key that fits into those locks. When it binds, it can either block or enhance the activity of the cell, depending on the lock it's interacting with. This interaction can lead to changes in how the cell behaves, which can be beneficial in treating certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Statocin CI brief — competitive landscape report
Statocin updates RSS · CI watch RSS

Frequently asked questions about Statocin

What is Statocin?

Statocin (CARGUTOCIN) is a cargutocin drug.

How does Statocin work?

Statocin works by binding to a specific target, although the exact target is unknown.

What is the generic name of Statocin?

CARGUTOCIN is the generic (nonproprietary) name of Statocin.

What drug class is Statocin in?

Statocin belongs to the cargutocin class. See all cargutocin drugs at /class/cargutocin.

What development phase is Statocin in?

Statocin is in Phase 2.

Drug class: All cargutocin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing